LRMR - Larimar Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LRMR is currently covered by 5 analysts with an average price target of $-0.13. This is a potential upside of $-3.83 (-103.51%) from yesterday's end of day stock price of $3.7.

Larimar Therapeutics's activity chart (see below) currently has 24 price targets and 45 ratings on display. The stock rating distribution of LRMR is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 24.61% with an average time for these price targets to be met of 306.25 days.

Highest price target for LRMR is $26, Lowest price target is $10, average price target is $19.25.

Most recent stock forecast was given by YATIN SUNEJA from GUGGENHEIM on 25-Jun-2025. First documented stock forecast 16-Oct-2015.

Currently out of the existing stock ratings of LRMR, 20 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$26

$22.34 (610.38%)

$26

1 months 19 days ago
(25-Jun-2025)

2/7 (28.57%)

$22.75 (700.00%)

411

Buy

$16

$12.34 (337.16%)

$15

4 months 19 days ago
(25-Mar-2025)

0/6 (0%)

$13.69 (592.64%)

Buy

$10

$6.34 (173.22%)

$13

4 months 19 days ago
(25-Mar-2025)

0/3 (0%)

$7.69 (332.90%)

Buy

$25

$21.34 (583.06%)

$25

1 years 2 months 13 days ago
(31-May-2024)

1/10 (10%)

$17 (212.50%)

728

Hold

2 years 10 months 25 days ago
(19-Sep-2022)

0/1 (0%)

$12 (70.59%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LRMR (Larimar Therapeutics) average time for price targets to be met?

On average it took 306.25 days on average for the stock forecasts to be realized with a an average price target met ratio 24.61

Which analyst has the current highest performing score on LRMR (Larimar Therapeutics) with a proven track record?

JASON BUTLER

Which analyst has the current lower performing score on LRMR (Larimar Therapeutics) with a proven track record?

JOEL BEATTY

Which analyst has the most public recommendations on LRMR (Larimar Therapeutics)?

Jason Butler works at JMP and has 5 price targets and 3 ratings on LRMR

Which analyst is the currently most bullish on LRMR (Larimar Therapeutics)?

Yatin Suneja with highest potential upside - $22.34

Which analyst is the currently most reserved on LRMR (Larimar Therapeutics)?

Edward Tenthoff with lowest potential downside - -$0

Larimar Therapeutics in the News

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters’ option...

Larimar Prices $60 Mln Public Offering Of 18.75M Shares At $3.20 Each

(RTTNews) – Larimar Therapeutics (LRMR) has priced its underwritten public offering of 18.75 million shares at $3.20 per share, aiming to raise $60 million in gross proceeds. The company also granted underwriters a 30-day option to purchase an additional 2.81 million shares. The offering is expected to close around July 31, 2025, pending customary conditions....

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?